2010 Scrip 100 - Stem cell trials, tribulations and trailblazers
This article was originally published in Scrip
Executive Summary
The prospects of true innovation have lured companies of all sizes into the stem cell space. The strategies being implemented by research groups are diverse and colourful, yet the regulatory terrain remains rough and the risks prohibitive, explains Asher Mullard.